We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+37.02%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$390M
AUM Growth
+$12.6M
Cap. Flow
-$64M
Cap. Flow %
-16.4%
Top 10 Hldgs %
30.29%
Holding
100
New
16
Increased
29
Reduced
38
Closed
17

Top Buys

Rank Stock Value
1
SDGR icon
Schrodinger
SDGR
+$6.67M
2
ARWR icon
Arrowhead Research
ARWR
+$4.3M
3
DXCM icon
DexCom
DXCM
+$4.27M
4
AVTR icon
Avantor
AVTR
+$3.89M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$3.76M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$12.7M
2
MRK icon
Merck
MRK
+$10.4M
3
AXNX
Axonics, Inc. Common Stock
AXNX
+$9.03M
4
MASI
Masimo
MASI
+$8.26M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$6.12M

Sector Composition

Rank Sector Weight
1 Healthcare 92.05%
2 Technology 1.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DXCM icon
1
DexCom
DXCM
$32B
$15.4M 3.93%
166,112
+47,836
+40% +$4.27M
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$12.9M 3.29%
175,712
-61,242
-26% -$4.55M
VCEL icon
3
Vericel Corp
VCEL
$2.31B
$12.4M 3.17%
400,743
-49,657
-11% -$1.18M
SDGR icon
4
Schrodinger
SDGR
$1.36B
$12.4M 3.17%
156,085
+106,085
+212% +$6.67M
ACRS icon
5
Aclaris Therapeutics
ACRS
$869M
$12.1M 3.11%
1,875,336
+32,675
+2% +$138K
NTRA icon
6
Natera
NTRA
$46.4B
$12M 3.08%
120,867
-54,294
-31% -$4.54M
DHR icon
7
Danaher
DHR
$144B
$10.6M 2.71%
53,791
-19,538
-27% -$3.92M
IQV icon
8
IQVIA
IQV
$39.3B
$10.4M 2.67%
58,224
+5,716
+11% +$963K
HUM icon
9
Humana
HUM
$46.2B
$10.2M 2.61%
24,808
-1,701
-6% -$707K
CRL icon
10
Charles River Laboratories
CRL
$12.8B
$9.91M 2.54%
39,666
-339
-0.8% -$80.7K
ARWR icon
11
Arrowhead Research
ARWR
$12.4B
$9.76M 2.5%
127,171
+67,171
+112% +$4.3M
GWPH
12
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$9.41M 2.41%
81,573
+31,573
+63% +$3.54M
GNMK
13
DELISTED
GenMark Diagnostics, Inc
GNMK
$9.02M 2.31%
617,722
+137,523
+29% +$1.82M
CTLT
14
DELISTED
CATALENT, INC.
CTLT
$8.75M 2.24%
84,119
-5,897
-7% -$572K
CDMO
15
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$8.65M 2.22%
749,511
+265,264
+55% +$2.43M
UNH icon
16
UnitedHealth
UNH
$370B
$8.41M 2.16%
23,993
+2,992
+14% +$1M
PODD icon
17
Insulet
PODD
$9.79B
$7.82M 2%
30,587
-1,916
-6% -$475K
KOD icon
18
Kodiak Sciences
KOD
$2.84B
$7.33M 1.88%
49,913
-42,820
-46% -$4.77M
DRNA
19
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$7.3M 1.87%
331,513
+5,650
+2% +$124K
ATEC icon
20
Alphatec Holdings
ATEC
$1.44B
$7.3M 1.87%
502,655
+50,983
+11% +$538K
TPTX
21
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$7.24M 1.85%
59,377
-50,958
-46% -$5.58M
ICAD
22
DELISTED
iCAD Inc
ICAD
$7.16M 1.84%
542,602
-39,150
-7% -$422K
XLRN
23
DELISTED
Acceleron Pharma
XLRN
$6.71M 1.72%
52,458
+2,442
+5% +$286K
SPNE
24
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$6.54M 1.68%
374,945
+6,132
+2% +$93.4K
RCUS icon
25
Arcus Biosciences
RCUS
$3.64B
$6.02M 1.54%
231,758
-3,280
-1% -$79.4K
1
2 3 4

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
SFO
Stokes Family Office New Orleans, Louisiana $969M AUM 19.6% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return

Parkman Healthcare Partners's Q4 2020 Portfolio in Review

As of Q4 2020, Parkman Healthcare Partners held 100 positions worth $390M, up 3.3% from $378M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Parkman Healthcare Partners withdrew a net $64M in Q4 2020, closing 17 positions and reducing 38 holdings. Its most notable exit was Neurocrine Biosciences, an estimated $12.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 92% a quarter earlier, followed by Technology.

Against the trend, Parkman Healthcare Partners opened a new position in Avantor worth $4.25M.

  • Parkman Healthcare Partners's largest Q4 2020 buy was Avantor: 150,872 shares worth $4.25M.
  • Parkman Healthcare Partners added most to Schrodinger in Q4 2020, an estimated $6.67M increase.
  • Parkman Healthcare Partners's biggest Q4 2020 reduction was Edwards Lifesciences, cutting an estimated $5.97M.
  • Parkman Healthcare Partners fully exited Neurocrine Biosciences in Q4 2020, selling an estimated $12.7M.
  • Parkman Healthcare Partners's ten largest holdings make up 30% of its $390M portfolio in Q4 2020.
  • Parkman Healthcare Partners opened 16 new positions and closed 17 in Q4 2020.
  • Parkman Healthcare Partners's portfolio value rose 3.3% quarter-over-quarter to $390M.

Based on Parkman Healthcare Partners's 13F filing for Q4 2020, filed 12 Feb 2021.